Who Owns Motrin?

Kenvue reports sustainability metrics through its Healthy Lives Mission program. The company has reduced Scope 1 and 2 emissions by 37% from a 2020 base year, working toward a 42% reduction goal by 2030. Kenvue has expanded renewable electricity to 72% of global operations, with Latin America maintaining 100% renewable electricity since 2023.

On packaging, 69% of Kenvue's packaging is recyclable or refillable, with a goal of 100% by 2025. The company has reduced virgin plastic use by 21.4% from a 2020 base year, targeting 25% by 2025 and 50% by 2030. Motrin-specific packaging improvements are not reported separately from Kenvue's consolidated metrics.

Motrin does not hold independent sustainability certifications such as B Corp status or cruelty-free certification, as these are not standard for pharmaceutical products. The brand is regulated by the FDA and subject to pharmaceutical manufacturing standards rather than consumer goods sustainability frameworks.

Kenvue donated more than $56 million to community health initiatives in 2024 through its Healthy People program.

Motrin does not have significant independent industry awards. The brand's recognition comes primarily from consumer trust surveys and healthcare professional recommendations. Motrin has been featured in Consumer Reports OTC pain reliever evaluations, where ibuprofen products are generally rated equivalently on efficacy.

Kenvue, Motrin's parent company, has received recognition for its sustainability initiatives. Kenvue's Healthy Lives Mission Report has been acknowledged by environmental organizations. The company's science-based emissions targets were validated by the Science Based Targets initiative.

Motrin itself has not received product-specific awards from independent testing organizations. The FDA regulates ibuprofen as a generally recognized as safe and effective (GRASE) OTC drug, which serves as the primary regulatory recognition of the product's safety profile when used as directed.

The FDA has strengthened warnings on non-aspirin NSAIDs, including ibuprofen, regarding potential cardiovascular risks. A 2015 FDA Drug Safety Communication warned that NSAIDs can increase the risk of heart attacks and strokes, particularly with long-term use or in patients with existing cardiovascular disease. This warning applies to all ibuprofen products, including Motrin, and requires updated labeling. The current status is that the FDA warning remains in effect, and Motrin packaging includes the required cardiovascular risk warning.

The FDA also requires ibuprofen products to carry allergy alerts warning of potential severe allergic reactions, especially in people allergic to aspirin. Cases of Stevens-Johnson syndrome, a rare but serious skin reaction, have been reported with ibuprofen use. Motrin packaging includes these warnings as required.

In 2010, Johnson & Johnson's McNeil Consumer Healthcare division, which manufactured Motrin at the time, faced congressional investigation over a "phantom recall" of Motrin products. The company had hired contractors to buy back potentially defective Motrin from store shelves without formally announcing a recall. Johnson & Johnson later acknowledged the issue and paid a $25 million settlement in 2015 to resolve criminal charges related to the handling of quality issues at its Fort Washington, Pennsylvania facility.

In April 2025, dozens of generic medications were recalled due to quality concerns at contract manufacturing facilities. Motrin was not directly affected by these recalls, but the incidents increased consumer awareness about medication quality standards across the OTC category.